Related Experiment Video
Updated: Apr 25, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Context-dependent synthetic lethality - an emerging precision therapeutic approach
Liang Chang1, Katharin Shaw1,2,3, Francisca Vazquez1
1Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Abstract:
Context-dependent synthetic lethality offers a promising strategy for expanding the scope of precision oncology beyond direct oncogene inhibition. We describe various genetic contexts that produce cancer-intrinsic vulnerabilities and consequent synthetic lethal opportunities. We also identify common mechanistic themes that underlie synthetic lethality, such as DNA repair defects, loss of functional redundancies, metabolic imbalances and narrow signalling tolerances. Whereas clinical translation has seen success - for example, with inhibitors of poly(ADP-ribose) polymerase (PARP), hypoxia-inducible factor 2 (HIF-2) and Smoothened (SMO), other targets require more nuanced strategies to achieve selectivity. Case studies highlight that therapeutic index, often inferable from functional genomics, is a critical determinant of success and should guide both target prioritization and therapeutic strategy. They also reveal that specific molecular mechanisms underlying the synthetic lethal phenotype can inform the discovery of the optimal therapeutic modality. Finally, we describe emerging approaches for synthetic lethal target discovery and drug development that enable diverse therapeutic strategies. Together, these insights provide a framework for translating synthetic lethality into more selective and durable cancer therapies.
Insights
Context-dependent synthetic lethality exploits cancer-specific vulnerabilities for precision oncology. This approach identifies genetic contexts and mechanisms, like DNA repair defects, to develop targeted therapies beyond direct oncogene inhibition.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Precision oncology aims to expand beyond direct oncogene inhibition.
- Context-dependent synthetic lethality presents a promising strategy for this expansion.
- Understanding cancer-intrinsic vulnerabilities is key to identifying synthetic lethal opportunities.
Purpose of the Study:
- To describe genetic contexts and mechanistic themes underlying synthetic lethality in cancer.
- To highlight clinical successes and challenges in translating synthetic lethality into therapies.
- To provide a framework for discovering and developing novel synthetic lethal cancer therapies.
Main Methods:
- Identification of genetic contexts leading to cancer-intrinsic vulnerabilities.
- Analysis of common mechanistic themes (e.g., DNA repair defects, metabolic imbalances).
- Review of clinical case studies and functional genomics data for therapeutic index assessment.
Main Results:
- Synthetic lethality arises from diverse genetic contexts and mechanisms like DNA repair defects and metabolic imbalances.
- Clinical successes include poly(ADP-ribose) polymerase (PARP), hypoxia-inducible factor 2 (HIF-2), and Smoothened (SMO) inhibitors.
- Therapeutic index, informed by functional genomics, is critical for target prioritization and strategy.
Conclusions:
- Synthetic lethality offers a framework for developing more selective and durable cancer therapies.
- Understanding molecular mechanisms informs optimal therapeutic modality selection.
- Emerging approaches facilitate diverse synthetic lethal target discovery and drug development.
More Related Videos
Related Concept Videos
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
In-vitro Mutagenesis
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
In vitro Mutagenesis

